CT
CTKB.US Cytek Biosciences Inc
- Market cap
- USD 764M
- P/E
- -
- P/B
- 2.24x
- ROE
- -15.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CTKB.US undervalued?
Graham numberThe Graham number of Cytek Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cytek Biosciences Inc fundamental analysis
No fundamental analysis for Cytek Biosciences Inc yet.
Cytek Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagest…
Full company profileCytek Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cytek Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 57.9M | 92.8M | 128M | 164M | 193M | 200M | 201M | 194M |
| Gross Profit | 28.7M | 51.7M | 79.1M | 101M | 109M | 111M | 104M | 108M |
| Operating Income | -17.3M | 13.7M | 9.16M | -1.80M | -27.8M | -20.5M | -40.4M | -51.0M |
| EBITDA | -16.0M | 15.4M | 8.92M | 9.49M | -4.41M | 4.79M | -17.4M | -39.1M |
| Net Income | -16.8M | 19.4M | 3.00M | 2.58M | -12.1M | -6.02M | -66.5M | -49.5M |
| EPS | -0.13 | 0.15 | 0.02 | 0.02 | -0.09 | -0.05 | -0.52 | -0.38 |
| Balance Sheet | ||||||||
| Total Assets | 70.4M | 220M | 463M | 519M | 494M | 500M | 462M | 446M |
| Total Liabilities | 112M | 236M | 57.9M | 93.9M | 101M | 104M | 120M | 125M |
| Shareholders' Equity | -41.7M | -16.0M | 405M | 425M | 393M | 396M | 342M | 321M |
| Cash & Short-term Investments | 30.1M | 165M | 365M | 341M | 262M | 278M | 262M | 256M |
| Total Debt | - | 2.77M | - | 18.1M | 14.1M | 17.0M | 23.7M | 24.7M |
| Cash Flow | ||||||||
| Operating Cash Flow | -13.7M | 15.2M | 4.63M | -12.2M | 5.28M | 25.4M | -4.69M | -7.76M |
| Capital Expenditure | 973K | 1.55M | 4.36M | 9.87M | 4.83M | 3.53M | 4.08M | 7.85M |
| Free Cash Flow | -14.7M | 13.6M | 266K | -22.1M | 454K | 21.9M | -8.77M | -15.6M |
| Ratios | ||||||||
| ROE | - | - | 0.7% | 0.6% | -3.1% | -1.5% | -19.5% | -15.4% |
| ROA | -23.9% | 8.8% | 0.6% | 0.5% | -2.5% | -1.2% | -14.4% | -11.1% |
| Net Profit Margin | -29.1% | 20.9% | 2.3% | 1.6% | -6.3% | -3.0% | -33.0% | -25.5% |
| Debt to Equity | - | - | - | 0.04x | 0.04x | 0.04x | 0.07x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cytek Biosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.47M | 0.01 | - |
| 2022 | USD 209K | 0.00 | 8.1% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cytek Biosciences Inc
- Insiders 8.68%
- Institutions 63.68%
- Public & others 27.64%
- Shares outstanding 131M
- Free float 106M
Top funds holding CTKB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.53M | 2.70% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.09M | 2.37% | 0.00% | Oct 2026 |
| Column Small Cap Select | 2.58M | 1.98% | -0.88% | Sep 2026 |
| Fidelity Small Cap Index | 1.35M | 1.03% | +1.36% | Aug 2026 |
| Royce Micro-Cap Trust | 1.32M | 1.01% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 1.14M | 0.87% | 0.00% | Oct 2026 |
| WPG Partners Select Small Cap Value Ins | 1.12M | 0.86% | +4.99% | Aug 2026 |
| iShares Biotechnology ETF | 925K | 0.71% | -2.12% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 805K | 0.62% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 708K | 0.54% | +1.34% | Sep 2026 |
| Goldman Sachs Small Cp Val Insghts Instl | 639K | 0.49% | +34.00% | Jul 2026 |
| Schwab US Small-Cap ETF™ | 602K | 0.46% | +0.24% | Oct 2026 |
| Royce Micro-Cap Invmt | 572K | 0.44% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 567K | 0.43% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 532K | 0.41% | +69.49% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 373K | 0.29% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 352K | 0.27% | +207.77% | Sep 2026 |
| DFA US Micro Cap I | 351K | 0.27% | +2.35% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 340K | 0.26% | +8.43% | Sep 2026 |
| Vanguard Health Care ETF | 332K | 0.25% | -2.46% | Sep 2026 |
Top institutions holding CTKB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 9.58M | 7.32% | -43.68% | Jun 2026 |
| Millennium Management LLC | 9.34M | 7.14% | +48.42% | Jun 2026 |
| Boston Partners Global Investors, Inc | 7.66M | 5.86% | +32.02% | Jun 2026 |
| Hillhouse Capital Advisors, Ltd. | 6.66M | 5.09% | 0.00% | Jun 2026 |
| Topline Capital Management LLC | 6.28M | 4.80% | -11.06% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.94M | 3.78% | +3.71% | Jun 2026 |
| Geode Capital Management, LLC | 3.06M | 2.34% | +7.96% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.57M | 1.96% | -1.87% | Sep 2026 |
| State Street Corp | 2.57M | 1.96% | -37.77% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.17M | 1.66% | -7.56% | Jun 2026 |
| Royce & Associates, LP | 2.08M | 1.59% | +26.74% | Jun 2026 |
| Acadian Asset Management LLC | 1.38M | 1.05% | +244.88% | Jun 2026 |
| Bank of America Corp | 1.32M | 1.01% | +30.35% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.14M | 0.87% | -50.62% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.07M | 0.82% | -2.84% | Jun 2026 |
| Northern Trust Corp | 1.00M | 0.77% | -0.19% | Jun 2026 |
| HRT FINANCIAL LLC | 998K | 0.76% | +140.98% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 974K | 0.74% | +204.41% | Jun 2026 |
| Jane Street Group LLC | 906K | 0.69% | 0.00% | Jun 2026 |
| Tudor Investment Corp Et AL | 838K | 0.64% | +161.26% | Jun 2026 |
Cytek Biosciences Inc company profile
- Company name
- Cytek Biosciences Inc
- Ticker
- CTKB.US
- Exchange
- USA Stocks
- Listed since
- Jul 23, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 703
- Fiscal year end
- December
- Address
- 47215 Lakeview Blvd, Fremont, CA, United States, 94538-6407
- Phone
- 877 922 9835
- Website
- cytekbio.com
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Cytek Biosciences Inc management
6- Dr. Wenbin Jiang Ph.D.President, CEO & Chairman of the Board · born 1964
- Mr. William D. McCombeChief Financial Officer · born 1958
- Dr. Ming Yan Ph.D.CTO & Director · born 1963
- Mr. Paul D. GoodsonHead of Investor Relations
- Mr. Ilan B. FeuchtwangChief Legal Officer
- Mr. Patrik Sebastian JeanmonodHead of Corporate Development Analytics · born 1966